SynAct Pharma has announced that its Phase IIb ADVANCE trial, evaluating lead asset resomelagon in patients with newly diagnosed rheumatoid arthritis (RA), is on-track to complete patient recruitment by end-2025, consistent with prior guided timelines, with 190 out of 240 participants now randomised. ADVANCE has been designed as a 12-week, randomised, placebo-controlled study. It is specifically targeting RA patients with high disease activity who are eligible for methotrexate treatment (the current standard of care). Top-line results are anticipated in Q126, and as this is the lead programme, it represents an important upcoming inflection point for SynAct.
Industrials | Comment
TMT | Comment
Industrials | Comment
Industrials | Comment